014950 — Samik Pharm Co Income Statement
0.000.00%
Last trade - 00:00- KR₩142bn
- KR₩124bn
- KR₩56bn
Annual income statement for Samik Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 51,229 | 55,857 |
| Cost of Revenue | ||
| Gross Profit | 33,935 | 38,805 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Depreciation and Amortization | ||
| Unusual Expense / Income | ||
| Total Operating Expenses | 48,433 | 52,203 |
| Operating Profit | 2,796 | 3,654 |
| Gain / Loss on Sale of Assets | ||
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | 3,423 | 4,353 |
| Provision for Income Taxes | ||
| Net Income After Taxes | 2,969 | 3,522 |
| Net Income Before Extraordinary Items | ||
| Net Income | 2,969 | 3,522 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | 2,969 | 3,522 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | 324 | 385 |
| Dividends per Share |